Dyadic International (DYAI) Gross Margin (2018 - 2025)
Dyadic International (DYAI) posted Gross Margin of 67.86% for Q1 2025, up 19.4% sequentially from 56.84% in Q4 2024, and down 3214.0% YoY from 2.18% in Q1 2024.
Dyadic International (DYAI) Gross Margin (2018 - 2025) Analysis & Trends
Dyadic International has reported Gross Margin for 8 years, with the latest figure at 67.86% in Q1 2025.
- Quarterly Gross Margin fell 3214.0% year-over-year to 67.86% in Q1 2025, while the trailing twelve-month figure through Mar 2025 was 66.88% (up 2226.0% YoY) and the FY2024 annual result came in at 65.82%, up 3398.0% from the prior year.
- Gross Margin rose to 67.86% in Q1 2025 per DYAI's latest filing, from 56.84% in the prior quarter.
- Over five years, Gross Margin peaked at 100.0% in Q1 2024 and troughed at 5.85% in Q4 2021.
- A 5-year average of 38.56% and a median of 37.57% in 2022 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2023 and 2024: Gross Margin tumbled 3229 bps in 2023, then jumped 7432 bps in 2024.
- Over 5 years, Gross Margin stood at 5.85% in 2021, then surged by 190 bps to 5.28% in 2022, then surged by 829 bps to 49.0% in 2023, then gained by 16 bps to 56.84% in 2024, then rose by 19 bps to 67.86% in 2025.
- According to Business Quant data, Gross Margin over the past three periods registered 67.86%, 56.84%, and 79.78% for Q1 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 76.90% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 63.27% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 84.20% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Dyadic International | 19.98 Mn | 19.98 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 67.86% |
| Dec 31, 2024 | 56.84% |
| Sep 30, 2024 | 79.78% |
| Jun 30, 2024 | 21.75% |
| Mar 31, 2024 | 100.00% |
| Dec 31, 2023 | 49.00% |
| Sep 30, 2023 | 73.34% |
| Jun 30, 2023 | 5.28% |
| Mar 31, 2023 | 25.68% |
| Dec 31, 2022 | 5.28% |
| Sep 30, 2022 | 31.46% |
| Jun 30, 2022 | 37.57% |
| Mar 31, 2022 | 37.58% |
| Dec 31, 2021 | -5.85% |
| Sep 30, 2021 | 43.35% |
| Jun 30, 2021 | 11.48% |
| Mar 31, 2021 | 15.15% |
| Dec 31, 2020 | 26.12% |
| Sep 30, 2020 | 35.89% |
| Jun 30, 2020 | -19.07% |